ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 37 filers reported holding ALIGOS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,725,394 | -23.1% | 2,309,764 | 0.0% | 0.04% | -18.8% |
| Q2 2023 | $2,242,781 | +11.1% | 2,309,764 | 0.0% | 0.05% | +33.3% |
| Q1 2023 | $2,018,734 | -8.3% | 2,309,764 | 0.0% | 0.04% | -21.7% |
| Q4 2022 | $2,200,974 | -15.4% | 2,309,764 | -2.3% | 0.05% | -32.4% |
| Q3 2022 | $2,602,000 | -9.1% | 2,365,064 | 0.0% | 0.07% | +11.5% |
| Q2 2022 | $2,862,000 | -43.7% | 2,365,064 | 0.0% | 0.06% | -42.5% |
| Q1 2022 | $5,085,000 | -81.9% | 2,365,064 | 0.0% | 0.11% | -75.6% |
| Q4 2021 | $28,073,000 | -23.5% | 2,365,064 | 0.0% | 0.43% | -9.6% |
| Q3 2021 | $36,682,000 | -16.9% | 2,365,064 | +9.2% | 0.48% | +5.7% |
| Q2 2021 | $44,135,000 | -10.4% | 2,165,064 | 0.0% | 0.45% | -6.8% |
| Q1 2021 | $49,234,000 | -17.8% | 2,165,064 | 0.0% | 0.49% | +2.3% |
| Q4 2020 | $59,864,000 | – | 2,165,064 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,320,381 | $47,301,000 | 15.67% |
| Pivotal bioVenture Partners Investment Advisor LLC | 876,548 | $17,873,000 | 7.04% |
| Vivo Capital, LLC | 3,547,030 | $72,306,000 | 3.13% |
| Novo Holdings A/S | 2,614,563 | $53,311,000 | 2.36% |
| ACUTA CAPITAL PARTNERS, LLC | 214,254 | $4,368,000 | 1.75% |
| Boxer Capital, LLC | 1,526,048 | $31,108,000 | 1.10% |
| VR Adviser, LLC | 408,377 | $8,325,000 | 1.01% |
| Cormorant Asset Management, LP | 905,467 | $18,458,000 | 0.63% |
| HHLR ADVISORS, LTD. | 2,165,064 | $44,135,000 | 0.45% |
| Logos Global Management LP | 212,785 | $4,339,000 | 0.36% |